Clinical Trial Update: Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immune response of MKC1106-PP in patients with advanced cancer, including ovarian cancer and melanoma; the study has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Ovarian Cancer

Drugs mentioned

• MKC1106-PP

Snippet

Sponsor: Mannkind Corporation | Conditions: Ovarian, Melanoma | Phase 1 | Status: COMPLETED